{"filing":{"accession_number":"0001185185-26-002410","cik":"0001326205","ticker":"IGC","company_name":"IGC Pharma, Inc.","form":"8-K","filing_date":"2026-06-08","report_date":null,"primary_document":"igc8k060826.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1326205/000118518526002410/igc8k060826.htm"},"events":[{"id":6167,"run_id":5415,"accession_number":"0001185185-26-002410","anchor_item_number":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"summary":"The filing discloses an amendment to extend IGC Pharma's Master Loan and Security Agreement with O-Bank Co., Ltd., increasing the facility fee from $48,000 to $60,000 while maintaining a $12,000,000 maximum aggregate limit. While Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of Direct Financial Obligation) are cited, this is a routine extension of an existing credit facility rather than a new material acquisition, debt covenant breach, or other specifically-defined event type. The modest fee increase and continuation of substantially unchanged terms suggest administrative renewal rather than a transformative financial event, though the extension of material debt facilities warrants disclosure as material to investors.","company_name":"IGC Pharma, Inc.","ticker":"IGC","filing_date":"2026-06-08","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":5158,"accession_number":"0001185185-26-002410","item_number":null,"item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses an amendment to extend IGC Pharma's Master Loan and Security Agreement with O-Bank Co., Ltd., increasing the facility fee from $48,000 to $60,000 while maintaining a $12,000,000 maximum aggregate limit. While Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of Direct Financial Obligation) are cited, this is a routine extension of an existing credit facility rather than a new material acquisition, debt covenant breach, or other specifically-defined event type. The modest fee increase and continuation of substantially unchanged terms suggest administrative renewal rather than a transformative financial event, though the extension of material debt facilities warrants disclosure as material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T20:04:36.307156+00:00","company_name":"IGC Pharma, Inc.","ticker":"IGC","filing_date":"2026-06-08"}]}